Mitsubishi Group Invests Additional $120M in a Liquidity Group Fund - Mars Growth, as it Ramps Up Growth Financing in ASIA PAC Tech Companies, Reaching $220M Direct MUFG Investment in Liquidity Within the Last 10 Months
1.9.2021 13:30:00 EEST | Business Wire | Press release
Mitsubishi Group (MUFG) the second largest banking and finance group in the world has injected another $120 million investment into the Mars Growth fund, a 50/50 joint venture owned by MUFG and Liquidity Capital. MUFG has a broader strategic relationship with Liquidity and this latest investment represents their cumulative investment of $220 million to date.
Mars Growth Capital provides debt financing solutions to technology companies in Asia Pacific and Europe. Since its inception one year ago, the fund has recorded exceptional performance through ten transactions to the value of $80 million, executed across Asia, Australia and Europe, with demand exceeding $2 billion during this period.
Through its strategic collaboration with MUFG, Liquidity is focused on revolutionizing the credit underwriting process for the business sector. Recognizing the challenges for high potential companies to secure non-dilutive capital from traditional financial institutions, Liquidity developed DYNAMiCS, a world-first, machine learning platform that can perform fast and thorough, data-driven due diligence on companies to assess their performance and growth potential.
DYNAMiCS uses algorithms to accurately predict future revenues, cash balances and other relevant financial covenants unique to technology business. Each of Liquidity’s four funds, including Mars Growth Fund, use the platform to inform their investment decision making, oftentimes in a process that takes less than 24-hours to complete.
Liquidity Group has provided over $750 million during the last year to over 50 growth companies across USA, Asia Pacific, Europe and the Middle East, including top unicorns such as eToro, Homer, Resident, Infinidat, Acronis, Infra.Market, and others. Its financing ranges from $5 million to $100 million, and is committed to 24-hour due diligence using its first of a kind platform - DYNAMiCS.
Ron Daniel, Liquidity CEO, said: “MUFG's ongoing investment in our funds is a vote of confidence in our technology, capabilities and potential. Mars Growth Capital’s performance to date is a reflection of the strength of our methodology of combining our team’s professional investing expertise with our bespoke DYNAMiCS technology solution. We are excited to continue our ongoing partnership with MUFG, who shares our ethos to support innovative, technology-driven companies across key market segments.”
Rio Hiroshima, who manages Mars Growth Capital’s operations on behalf of MUFG, said, “Since launching the fund just one year ago, we have quickly positioned ourselves as the market leader in growth financing for technology companies across the APAC and EMEA regions. Market demand, coupled with our strong investment performance has enabled us to grow rapidly and increase the value of the fund to $200 million. We are excited to continue our partnership with MUFG as we continue on the same dizzying trajectory into 2022”.
Yaron Primovich, the fund manager on behalf of Liquidity said: "Our partners at MUFG believe in our value proposition, and share our ambitions to be the global leader in growth financing. We hold a unique position in the marketplace because our underwriting platform acts as a data-driven oracle to identify and assess the potential of prospect companies. DYNAMiCS can cut through masses of information to analyse the strength of different business models, end customer behaviours and financial situations, arming us with insights to determine a company's ability to meet future debt repayments.”
"In a post Covid-world, businesses across the globe are on the cusp of even greater levels of innovation and expansion, further fuelling companies' appetite for growth and debt without dilution. We are excited to play a crucial role in helping these companies optimise on this opportunity”.
In addition, Mars Growth Capital has registered high levels of demand from hundreds of companies, in less than one year since its formation.
Notes to Editor
About Liquidity
Liquidity was established in 2018 by Ron Daniel, Yaron Sela and Oron Maymon. Liquidity manages $800 million in several funds worldwide. Among the partners in the company are Spark Capital, Meitav Dash and the Mitsubishi Banking Corporation. The company is considered a world leader in business credit management for growth companies using the machine learning technology it has developed. www.liquiditycap.com
Mars Growth is a joint venture between Liquidity Capital and MUFG that offers tech startups a one-of-a-kind funding alternative, enabling them to double down on their hyper-growth without giving up equity. Its trajectory-based funding model allows them to work with startups and growth-stage companies side-by-side, taking on financial risk. Part of the Liquidity funds arm, Mars Growth invests in SaaS providers that demonstrate over $3M in ARR and 30% year-over-year growth, with an average ticket size of $3M-$100M.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005448/en/
Contact information
Alex Bayliss
liquiditycapitaluk@fullyvested.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom